MarketCap
Facebook
X
Telegram
Sundial Growers Net Income | SNDL
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Sundial Growers
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.8 M | -96.2 M | -177 M | -372 M | -230 M | -240 M | -271 M | -13 M | -1.55 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.55 M | -372 M | -157 M |
Quarterly Net Income Sundial Growers
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.8 M | -96.2 M | -177 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -15.8 M | -177 M | -96.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Perrigo Company plc
PRGO
|
-1.43 B | $ 15.79 | -1.16 % | $ 2.19 B |  USA |
 |
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
-8.32 M | - | - | $ 50.1 M | USA |
 |
Bausch Health Companies
BHC
|
157 M | $ 6.35 | -1.55 % | $ 2.36 B |  Canada |
 |
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M |  Irlanda |
 |
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | USA |
 |
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | USA |
 |
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | USA |
 |
Evoke Pharma
EVOK
|
-5.35 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.41 M | $ 5.14 | -39.46 % | $ 76.4 M | USA |
 |
Cronos Group
CRON
|
-2.9 M | $ 3.33 | -0.6 % | $ 1.28 B | Canada |
 |
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M | USA |
 |
Emergent BioSolutions
EBS
|
52.6 M | $ 6.37 | 2.25 % | $ 341 M | USA |
 |
Evolus
EOLS
|
-51.6 M | $ 7.15 | 2.0 % | $ 461 M | USA |
 |
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
OptiNose
OPTN
|
-21.5 M | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | USA |
 |
Aurora Cannabis
ACB
|
1.59 M | $ 3.93 | 1.16 % | $ 215 M | Canada |
 |
Harrow Health
HROW
|
-5.14 M | $ 28.67 | 0.81 % | $ 1.05 B | USA |
 |
Canopy Growth Corporation
CGC
|
-263 M | $ 0.67 | -1.41 % | $ 200 M | Canada |
 |
Organogenesis Holdings
ORGO
|
37 M | $ 0.96 | -3.58 % | $ 122 M | USA |
 |
SCYNEXIS
SCYX
|
-8.61 M | $ 3.87 | 2.27 % | $ 193 M | USA |
 |
Solid Biosciences
SLDB
|
-174 M | $ 5.8 | -2.03 % | $ 508 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.18 M | $ 1.12 | 0.9 % | $ 1.89 M | USA |
 |
Tilray
TLRY
|
-121 M | $ 2.7 | -3.91 % | $ 302 M | Canada |
 |
TherapeuticsMD
TXMD
|
-569 K | $ 1.81 | 0.56 % | $ 20.9 M | USA |
 |
Pacira BioSciences
PCRX
|
7 M | $ 36.4 | -0.05 % | $ 1.62 B | USA |
 |
Veru
VERU
|
-22.7 M | $ 2.21 | -1.34 % | $ 32.4 M | USA |
 |
Viatris
VTRS
|
-3.51 B | $ 18.32 | 1.76 % | $ 21 B | USA |
 |
Rockwell Medical
RMTI
|
-5.31 M | $ 6.93 | -0.09 % | $ 249 M | USA |
 |
OrganiGram Holdings
OGI
|
-45.4 M | $ 0.93 | 0.92 % | $ 88.6 M | Canada |
 |
China Pharma Holdings
CPHI
|
-3.19 M | $ 0.63 | -2.4 % | $ 2.7 M |  China |
 |
Relmada Therapeutics
RLMD
|
-57.4 M | $ 3.26 | -0.31 % | $ 129 M | USA |
 |
cbdMD
YCBD
|
-2.04 M | $ 0.37 | 1.16 % | $ 1.49 M | USA |
 |
HEXO Corp.
HEXO
|
-1.07 B | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-466 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-14.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
-30.4 M | - | - | $ 150 M | USA |
 |
Jupiter Wellness
JUPW
|
-68.2 M | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-90.4 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
-14.7 M | - | - | $ 5.07 M | USA |